Telormedix Gets $7M for Bladder Cancer Therapy
By Cormac Sheridan
Monday, December 2, 2013
Telormedix SA took in CHF6 million (US$6.6 million) in a Series B funding round to enable it to complete an ongoing Phase II study of its lead drug TMX-101 in bladder cancer patients and to begin preparations for a potentially pivotal study in 2014. The cash takes the company’s total equity investment to CHF34.5 million.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.